e10vq
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
(Mark One)
|
|
þ
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended September 28, 2008
OR
|
|
o |
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the transition period
from
to .
Commission file number 1-5353
TELEFLEX INCORPORATED
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
23-1147939
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. employer identification
no.)
|
|
|
|
155 South Limerick Road,
Limerick, Pennsylvania
|
|
19468
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(610) 948-5100
(Registrants telephone
number, including area code)
(None)
(Former Name, Former Address and
Former Fiscal Year, If Changed Since Last Report)
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated
filer þ
|
|
Accelerated
filer o
|
|
Non-accelerated
filer o
|
|
Smaller reporting
company o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Act).
Yes o No þ
On October 20, 2008, 39,714,392 shares of the
registrants common stock, $1.00 par value, were
outstanding.
TELEFLEX
INCORPORATED
QUARTERLY REPORT ON
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 28, 2008
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
PART I FINANCIAL INFORMATION
|
|
|
|
|
Item 1:
|
|
Financial Statements:
|
|
|
|
|
|
|
Condensed Consolidated Statements of Income for the three and
nine months ended September 28, 2008 and September 30,
2007 (Unaudited)
|
|
|
2
|
|
|
|
Condensed Consolidated Balance Sheets as of September 28,
2008 and December 31, 2007 (Unaudited)
|
|
|
3
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the nine
months ended September 28, 2008 and September 30, 2007
(Unaudited)
|
|
|
4
|
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
5
|
|
Item 2:
|
|
Managements Discussion and Analysis of Financial Condition
and Results of Operations
|
|
|
23
|
|
Item 3:
|
|
Quantitative and Qualitative Disclosures About Market Risk
|
|
|
30
|
|
Item 4:
|
|
Controls and Procedures
|
|
|
30
|
|
|
|
PART II OTHER INFORMATION
|
|
|
|
|
Item 1:
|
|
Legal Proceedings
|
|
|
31
|
|
Item 1A:
|
|
Risk Factors
|
|
|
32
|
|
Item 2:
|
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
|
|
32
|
|
Item 3:
|
|
Defaults Upon Senior Securities
|
|
|
32
|
|
Item 4:
|
|
Submission of Matters to a Vote of Security Holders
|
|
|
32
|
|
Item 5:
|
|
Other Information
|
|
|
32
|
|
Item 6:
|
|
Exhibits
|
|
|
33
|
|
|
|
|
|
|
SIGNATURES
|
|
|
34
|
|
1
PART I
FINANCIAL INFORMATION
|
|
Item 1.
|
Financial
Statements
|
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars and shares in thousands, except per share)
|
|
|
Net revenues
|
|
$
|
595,882
|
|
|
$
|
458,562
|
|
|
$
|
1,824,487
|
|
|
$
|
1,351,219
|
|
Materials, labor and other product costs
|
|
|
357,064
|
|
|
|
304,585
|
|
|
|
1,094,165
|
|
|
|
872,464
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
238,818
|
|
|
|
153,977
|
|
|
|
730,322
|
|
|
|
478,755
|
|
Selling, engineering and administrative expenses
|
|
|
144,329
|
|
|
|
95,621
|
|
|
|
459,047
|
|
|
|
297,486
|
|
Restructuring and impairment charges
|
|
|
470
|
|
|
|
4,937
|
|
|
|
11,917
|
|
|
|
6,459
|
|
Net (gain) loss on sales of businesses and assets
|
|
|
|
|
|
|
(207
|
)
|
|
|
18
|
|
|
|
1,121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest, taxes and
minority interest
|
|
|
94,019
|
|
|
|
53,626
|
|
|
|
259,340
|
|
|
|
173,689
|
|
Interest expense
|
|
|
28,999
|
|
|
|
9,891
|
|
|
|
91,472
|
|
|
|
28,568
|
|
Interest income
|
|
|
(627
|
)
|
|
|
(4,599
|
)
|
|
|
(2,134
|
)
|
|
|
(7,922
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxes and minority
interest
|
|
|
65,647
|
|
|
|
48,334
|
|
|
|
170,002
|
|
|
|
153,043
|
|
Taxes on income from continuing operations
|
|
|
13,701
|
|
|
|
104,358
|
|
|
|
41,173
|
|
|
|
128,174
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations before minority interest
|
|
|
51,946
|
|
|
|
(56,024
|
)
|
|
|
128,829
|
|
|
|
24,869
|
|
Minority interest in consolidated subsidiaries, net of tax
|
|
|
9,627
|
|
|
|
7,200
|
|
|
|
25,779
|
|
|
|
21,016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
|
42,319
|
|
|
|
(63,224
|
)
|
|
|
103,050
|
|
|
|
3,853
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) from discontinued operations (including
(loss) on disposal of $4,808 in 2008 and (loss) gain on disposal
of ($275) and $75,215 in 2007, respectively)
|
|
|
|
|
|
|
7,439
|
|
|
|
(4,808
|
)
|
|
|
118,409
|
|
Taxes (benefit) on income (loss) from discontinued operations
|
|
|
|
|
|
|
1,251
|
|
|
|
(1,963
|
)
|
|
|
41,163
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
6,188
|
|
|
|
(2,845
|
)
|
|
|
77,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
42,319
|
|
|
$
|
(57,036
|
)
|
|
$
|
100,205
|
|
|
$
|
81,099
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
1.07
|
|
|
$
|
(1.61
|
)
|
|
$
|
2.61
|
|
|
$
|
0.10
|
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
0.16
|
|
|
|
(0.07
|
)
|
|
|
1.97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
1.07
|
|
|
$
|
(1.45
|
)
|
|
$
|
2.53
|
|
|
$
|
2.07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
1.06
|
|
|
$
|
(1.61
|
)
|
|
$
|
2.59
|
|
|
$
|
0.10
|
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
0.16
|
|
|
|
(0.07
|
)
|
|
|
1.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
1.06
|
|
|
$
|
(1.45
|
)
|
|
$
|
2.52
|
|
|
$
|
2.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends per share
|
|
$
|
0.34
|
|
|
$
|
0.32
|
|
|
$
|
1.00
|
|
|
$
|
0.925
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
39,645
|
|
|
|
39,368
|
|
|
|
39,553
|
|
|
|
39,207
|
|
Diluted
|
|
|
39,970
|
|
|
|
39,368
|
|
|
|
39,837
|
|
|
|
39,638
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
2
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 28,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
ASSETS
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
91,397
|
|
|
$
|
201,342
|
|
Accounts receivable, net
|
|
|
342,612
|
|
|
|
341,963
|
|
Inventories
|
|
|
430,180
|
|
|
|
419,188
|
|
Prepaid expenses
|
|
|
21,267
|
|
|
|
31,051
|
|
Income taxes receivable
|
|
|
64,845
|
|
|
|
|
|
Deferred tax assets
|
|
|
52,621
|
|
|
|
12,025
|
|
Assets held for sale
|
|
|
3,312
|
|
|
|
4,241
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,006,234
|
|
|
|
1,009,810
|
|
Property, plant and equipment, net
|
|
|
413,434
|
|
|
|
430,976
|
|
Goodwill
|
|
|
1,497,758
|
|
|
|
1,502,256
|
|
Intangibles and other assets
|
|
|
1,150,658
|
|
|
|
1,211,172
|
|
Investments in affiliates
|
|
|
26,989
|
|
|
|
26,594
|
|
Deferred tax assets
|
|
|
2,168
|
|
|
|
7,189
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
4,097,241
|
|
|
$
|
4,187,997
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
89,915
|
|
|
$
|
143,357
|
|
Accounts payable
|
|
|
144,280
|
|
|
|
133,654
|
|
Accrued expenses
|
|
|
158,084
|
|
|
|
180,110
|
|
Payroll and benefit-related liabilities
|
|
|
85,427
|
|
|
|
84,251
|
|
Income taxes payable
|
|
|
27,600
|
|
|
|
85,805
|
|
Deferred tax liabilities
|
|
|
21,523
|
|
|
|
21,733
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
526,829
|
|
|
|
648,910
|
|
Long-term borrowings
|
|
|
1,488,396
|
|
|
|
1,540,902
|
|
Deferred tax liabilities
|
|
|
399,138
|
|
|
|
379,467
|
|
Pension and postretirement benefit liabilities
|
|
|
91,001
|
|
|
|
78,910
|
|
Other liabilities
|
|
|
169,850
|
|
|
|
168,782
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
2,675,214
|
|
|
|
2,816,971
|
|
Minority interest in equity of consolidated subsidiaries
|
|
|
35,408
|
|
|
|
42,183
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
1,386,619
|
|
|
|
1,328,843
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
$
|
4,097,241
|
|
|
$
|
4,187,997
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
3
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Cash Flows from Operating Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
100,205
|
|
|
$
|
81,099
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
Loss (income) from discontinued operations
|
|
|
2,845
|
|
|
|
(77,246
|
)
|
Depreciation expense
|
|
|
48,997
|
|
|
|
34,011
|
|
Amortization expense of intangible assets
|
|
|
35,064
|
|
|
|
8,925
|
|
Amortization expense of deferred financing costs
|
|
|
3,931
|
|
|
|
838
|
|
Stock-based compensation
|
|
|
6,578
|
|
|
|
6,404
|
|
Net loss on sales of businesses and assets
|
|
|
18
|
|
|
|
1,121
|
|
Impairment of long-lived assets
|
|
|
|
|
|
|
4,118
|
|
Minority interest in consolidated subsidiaries
|
|
|
25,779
|
|
|
|
21,016
|
|
Other
|
|
|
15,301
|
|
|
|
(2,409
|
)
|
Changes in operating assets and liabilities, net of effects of
acquisitions:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(12,636
|
)
|
|
|
(24,354
|
)
|
Inventories
|
|
|
(14,850
|
)
|
|
|
(4,212
|
)
|
Prepaid expenses
|
|
|
9,619
|
|
|
|
(9,799
|
)
|
Accounts payable and accrued expenses
|
|
|
11,516
|
|
|
|
5,759
|
|
Income taxes payable and deferred income taxes
|
|
|
(134,219
|
)
|
|
|
107,869
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities from continuing
operations
|
|
|
98,148
|
|
|
|
153,140
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Proceeds from long-term borrowings
|
|
|
77,000
|
|
|
|
49,203
|
|
Repayments of long-term borrowings
|
|
|
(185,345
|
)
|
|
|
(30,689
|
)
|
Increase (decrease) in notes payable and current borrowings
|
|
|
2,386
|
|
|
|
(10,663
|
)
|
Proceeds from stock compensation plans
|
|
|
7,717
|
|
|
|
23,167
|
|
Payments to minority interest shareholders
|
|
|
(33,079
|
)
|
|
|
(21,259
|
)
|
Dividends
|
|
|
(39,568
|
)
|
|
|
(36,321
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities from continuing operations
|
|
|
(170,889
|
)
|
|
|
(26,562
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Expenditures for property, plant and equipment
|
|
|
(28,292
|
)
|
|
|
(30,153
|
)
|
Payments for businesses acquired
|
|
|
(5,673
|
)
|
|
|
(43,689
|
)
|
Proceeds from sales of businesses and assets
|
|
|
6,681
|
|
|
|
142,303
|
|
Purchase of intellectual property
|
|
|
(410
|
)
|
|
|
|
|
Investments in affiliates
|
|
|
(320
|
)
|
|
|
(5,439
|
)
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities from
continuing operations
|
|
|
(28,014
|
)
|
|
|
63,022
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Discontinued Operations:
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by operating activities
|
|
|
(5,616
|
)
|
|
|
60,509
|
|
Net cash provided by financing activities
|
|
|
|
|
|
|
3,391
|
|
Net cash used in investing activities
|
|
|
|
|
|
|
(11,588
|
)
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by discontinued operations
|
|
|
(5,616
|
)
|
|
|
52,312
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(3,574
|
)
|
|
|
7,403
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(109,945
|
)
|
|
|
249,315
|
|
Cash and cash equivalents at the beginning of the period
|
|
|
201,342
|
|
|
|
248,409
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of the period
|
|
$
|
91,397
|
|
|
$
|
497,724
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
4
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
Note 1
|
Basis of
presentation
|
Teleflex Incorporated (the Company) is a diversified
company specializing in the design, manufacture and distribution
of specialty-engineered products. The Company serves a wide
range of customers in segments of the medical, aerospace and
commercial industries. The Companys products include:
devices used in critical care applications, surgical
instruments, and cardiac assist devices for hospitals and
healthcare providers, and instruments and devices delivered to
medical device manufacturers; engine repair products and
services and cargo-handling systems and equipment used in
commercial aircraft; and marine driver controls, and engine
assemblies and drive parts, power and fuel management systems
and rigging products and services for commercial industries.
The accompanying condensed consolidated financial statements of
the Company have been prepared in accordance with accounting
principles generally accepted in the United States of America
(US GAAP) for interim financial information and in
accordance with the instructions for
Form 10-Q
and
Rule 10-01
of
Regulation S-X.
Accordingly, they do not include all information and footnotes
required by US GAAP for complete financial statements.
The accompanying financial information is unaudited; however, in
the opinion of the Companys management, all adjustments
(consisting of normal recurring adjustments and accruals)
necessary for a fair statement of the financial position,
results of operations and cash flows for the periods reported
have been included. The results of operations for the periods
reported are not necessarily indicative of those that may be
expected for a full year.
This quarterly report should be read in conjunction with the
consolidated financial statements and notes thereto included in
the Companys audited consolidated financial statements for
the fiscal year ended December 31, 2007.
Certain reclassifications have been made to the prior year
condensed consolidated financial statements to conform to
current period presentation, including the reclassification of
$41.8 million of borrowings under the revolving credit
agreement from current borrowings to long-term borrowings.
Certain financial information is presented on a rounded basis,
which may cause minor differences.
|
|
Note 2
|
New
accounting standards
|
Split-Dollar Life Insurance Arrangements: In
March 2007, the Financial Accounting Standards Board
(FASB) ratified the consensus reached by the
Emerging Issues Task Force (EITF) for Issue
06-10
Accounting for Collateral Assignment Split-Dollar Life
Insurance Arrangements.
EITF 06-10
provides guidance for determining when a liability exists for
the postretirement benefit obligation as well as recognition and
measurement of the associated asset on the basis of the terms of
the collateral assignment agreement. The Company adopted the
requirements of
EITF 06-10
on January 1, 2008, as a change in accounting principle
through a cumulative-effect adjustment that reduced retained
earnings by approximately $1.9 million. The adjustment was
determined by assessing the future cash flows of the premiums
that were paid to date as of December 31, 2007 that the
Company is entitled to recover under the split-dollar life
insurance arrangements, resulting in a reduction of other assets
by $1.9 million. Currently, the Company has not made
premium payments on any of these policies since 2003.
Fair Value Measurements: In September 2006,
the FASB issued Statement of Financial Accounting Standards
(SFAS) No. 157, Fair Value
Measurements. SFAS No. 157 establishes a common
definition of fair value to be applied to US GAAP that requires
the use of fair value, establishes a framework for measuring
fair value, and expands disclosure about such fair value
measurements. Except as noted below, SFAS No. 157
became effective for fiscal years beginning after
November 15, 2007.
In February 2008, the FASB issued FASB Staff Position
(FSP)
157-2,
Partial Deferral of the Effective Date of Statement
157.
FSP 157-2
delays the effective date of SFAS No. 157 to fiscal
years beginning after November 15, 2008 for all
nonfinancial assets and nonfinancial liabilities, except those
that are recognized or disclosed at fair value in the financial
statements on a recurring basis (at least annually). The Company
adopted SFAS No. 157 as of January 1, 2008 with
respect to financial assets and financial liabilities. The
Company is
5
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
currently evaluating the impact of SFAS No. 157
related to nonfinancial assets and nonfinancial liabilities on
the Companys financial position, results of operations and
cash flows.
In October 2008, the FASB issued
FSP 157-3,
Determining the Fair Value of a Financial Asset When the
Market for That Asset is Not Active.
FSP 157-3
clarifies the application of SFAS No. 157 in a market
that is not active and provides an example to illustrate key
considerations in determining the fair value of a financial
asset when the market for that financial asset is not active.
FSP 157-3
became effective upon issuance and did not have a material
impact on the Companys fair value of financial assets as a
result of the adoption of
FSP 157-3.
Refer to Note 11 for additional information on fair value
measurements.
Fair Value Option: In February 2007, the FASB
issued SFAS No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities including
an amendment of FASB Statement No. 115, which permits
an entity to measure certain financial assets and financial
liabilities at fair value, with unrealized gains and losses
reported in earnings at each subsequent measurement date. The
fair value option may be elected on an
instrument-by-instrument
basis, as long as it is applied to the instrument in its
entirety. The fair value option election is irrevocable, unless
an event specified in SFAS No. 159 occurs that results
in a new election date. This statement is effective for fiscal
years beginning after November 15, 2007. The Company
adopted SFAS No. 159 as of January 1, 2008 and
has elected not to measure any additional financial instruments
and other items at fair value.
Business Combinations: In December 2007, the
FASB issued SFAS No. 141(R), Business
Combinations. SFAS No. 141(R) replaces
SFAS No. 141, Business Combinations.
SFAS No. 141(R) retains the fundamental requirements
in Statement 141 that the acquisition method of accounting
(which Statement 141 called the purchase method) be used
for all business combinations and for an acquirer to be
identified for each business combination.
SFAS No. 141(R) defines the acquirer as the entity
that obtains control of one or more businesses in the business
combination and establishes the acquisition date as the date
that the acquirer achieves control.
SFAS No. 141(R)s scope is broader than that of
Statement 141, which applied only to business combinations in
which control was obtained by transferring consideration.
SFAS No. 141(R) replaces Statement 141s
cost-allocation process and requires an acquirer to recognize
the assets acquired, the liabilities assumed, and any
noncontrolling interest in the acquiree at the acquisition date,
measured at their fair values as of that date, with limited
exceptions. In addition, SFAS No. 141(R) changes the
allocation and treatment of acquisition-related costs,
restructuring costs that the acquirer expected but was not
obligated to incur, the recognition of assets and liabilities
assumed arising from contingencies and the recognition and
measurement of goodwill. This statement is effective for fiscal
years beginning after December 15, 2008 and is to be
applied prospectively to business combinations. Accordingly, the
Company will apply the provisions of SFAS No. 141(R)
upon adoption on its effective date.
Noncontrolling Interests: In December 2007,
the FASB issued SFAS No. 160, Noncontrolling
Interests in Consolidated Financial Statements an
amendment of ARB No. 51. SFAS No. 160
amends Accounting Research Bulletin (ARB) 51 to
establish accounting and reporting standards for the
noncontrolling interest in a subsidiary, sometimes referred to
as minority interest, and for the deconsolidation of a
subsidiary. It clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial
statements. SFAS No. 160 requires that a
noncontrolling interest in subsidiaries held by parties other
than the parent be clearly identified, labeled, and presented in
the consolidated statement of financial position within equity,
but separate from the parents equity, that the amount of
consolidated net income attributable to the parent and to the
noncontrolling interest be clearly identified and presented on
the face of the consolidated statement of income, that the
changes in a parents ownership interest while the parent
retains its controlling financial interest in its subsidiary be
accounted for consistently as equity transactions and that when
a subsidiary is deconsolidated, any retained noncontrolling
equity investment in the former subsidiary be initially measured
at fair value. This statement is effective for fiscal years
beginning after December 15, 2008 and earlier adoption is
prohibited. Accordingly, the Company will apply the provisions
of SFAS No. 160 upon adoption on its effective date.
6
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Disclosures about Derivative Instruments and Hedging
Activities: In March 2008, the FASB issued
SFAS No. 161 Disclosures about Derivative
Instruments and Hedging Activities an amendment of
FASB Statement No. 133, which requires enhanced
disclosures about derivative and hedging activities. Companies
will be required to provide enhanced disclosures about
(a) how and why a company uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under SFAS No. 133 and related
interpretations, and (c) how derivative instruments and
related hedged items affect the companys financial
position, financial performance, and cash flows.
SFAS No. 161 is effective for financial statements
issued for fiscal and interim periods beginning after
November 15, 2008. Accordingly, the Company will ensure
that it meets the enhanced disclosure provisions of
SFAS No. 161 upon the effective date.
Hierarchy of Generally Accepted Accounting
Principles: In May 2008, the FASB issued
SFAS No. 162 The Hierarchy of Generally Accepted
Accounting Principles, which has been established by the
FASB as a framework for entities to identify the sources of
accounting principles and for selecting the principles to be
used in the preparation of financial statements of
nongovernmental entities that are presented in conformity with
US GAAP. SFAS No. 162 is not expected to result in a
change in current practices. SFAS No. 162 is effective
60 days following the Securities and Exchange
Commissions (SEC) approval of the Public
Company Accounting Oversight Boards (PCAOB)
amendments to AU Section 411, The Meaning of Present
Fairly in Conformity With Generally Accepted Accounting
Principles. Accordingly, the Company will adopt
SFAS No. 162 within the required period.
Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating
Securities: In June 2008, the FASB issued FSP
EITF 03-6-1
Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating Securities, which
addresses whether unvested instruments granted in share-based
payment transactions that contain nonforfeitable rights to
dividends or dividend equivalents are participating securities
subject to the two-class method of computing earnings per share
under SFAS No. 128, Earnings Per Share.
FSP
EITF 03-6-1
is effective for financial statements issued for fiscal years
beginning after December 15, 2008 and interim periods
within those years. The Company is currently evaluating the
guidance under FSP
EITF 03-6-1
but does not expect it will result in a change in the
Companys earnings per share or diluted earnings per share.
Determination of the Useful Life of Intangible
Assets: In April 2008, the FASB issued
FSP 142-3,
Determination of the Useful Life of Intangible
Assets, which amends the factors that should be considered
in developing renewal or extension assumptions used to determine
the useful life of a recognized intangible asset under
SFAS No. 142, Goodwill and Intangible
Assets.
FSP 142-3
is effective for fiscal years beginning after December 15,
2008. The Company is currently evaluating the guidance under
FSP 142-3
on the Companys consolidated financial position.
Acquisition
of Arrow International, Inc.
On October 1, 2007, the Company acquired all of the
outstanding capital stock of Arrow International, Inc.
(Arrow) for approximately $2.1 billion. Arrow
is a global provider of catheter-based access and therapeutic
products for critical and cardiac care. The transaction was
financed with cash, borrowings under a new senior secured
syndicated bank loan and proceeds received through the issuance
of privately placed notes. The results of operations for Arrow
are included in the Companys Medical Segment from the date
of acquisition.
Under the terms of the transaction, the Company paid $45.50 per
common share in cash, or $2,094.6 million in total, to
acquire all of the outstanding common shares of Arrow. In
addition, the Company paid $39.1 million in cash for
outstanding stock options of Arrow. Pursuant to the terms of the
agreement, upon the closing of the transaction, Arrows
outstanding stock options became fully vested and exercisable
and were cancelled in exchange for the right
7
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
to receive an amount for each underlying share equal to the
excess of $45.50 over the exercise price per share of the
option. The aggregate purchase price of $2,104.0 million
includes transaction costs of approximately $10.8 million.
In conjunction with the acquisition of Arrow, the Company repaid
approximately $35.1 million of debt, representing
substantially all of Arrows existing outstanding debt as
of October 1, 2007.
The Company financed the all cash purchase price and related
transaction costs associated with the Arrow acquisition and the
repayment of substantially all of Arrows outstanding debt
with $1,672.0 million from borrowings under a new senior
secured syndicated bank loan and proceeds received through the
issuance of privately placed notes and approximately
$433.5 million from cash on hand.
The acquisition of Arrow was accounted for under the purchase
method of accounting. As such, the cost to acquire Arrow was
allocated to the respective assets and liabilities acquired
based on their preliminary estimated fair values as of the
closing date.
The following table summarizes the revised purchase price
allocation of the cost to acquire Arrow based on the preliminary
fair values as of October 1, 2007:
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
Assets
|
|
|
|
|
Current assets
|
|
$
|
401.4
|
|
Property, plant and equipment
|
|
|
184.1
|
|
Intangible assets
|
|
|
930.4
|
|
Goodwill
|
|
|
1,044.0
|
|
Other assets
|
|
|
52.3
|
|
|
|
|
|
|
Total assets acquired
|
|
$
|
2,612.2
|
|
|
|
|
|
|
Less:
|
|
|
|
|
Current liabilities
|
|
$
|
127.4
|
|
Deferred tax liabilities
|
|
|
330.0
|
|
Other long-term liabilities
|
|
|
50.8
|
|
|
|
|
|
|
Liabilities assumed
|
|
$
|
508.2
|
|
|
|
|
|
|
Net assets acquired
|
|
$
|
2,104.0
|
|
|
|
|
|
|
The Company is continuing to evaluate the initial purchase price
allocation as of the acquisition date, which will be adjusted as
additional information related to the fair values of assets
acquired and liabilities assumed becomes known.
Certain assets acquired in the Arrow merger qualify for
recognition as intangible assets apart from goodwill in
accordance with SFAS No. 141, Business
Combinations. The preliminary estimated fair value of
intangible assets acquired included customer related intangibles
of $497.7 million, trade names of $249.0 million and
purchased technology of $153.4 million. Customer related
intangibles have a useful life of 25 years and purchased
technology have useful lives ranging from 7-15 years. Trade
names have an indefinite useful life. A portion of the purchase
price allocation, $30 million, representing in-process
research and development was deemed to have no future
alternative use and was charged to expense as of the date of the
combination. Goodwill is not deductible for tax purposes.
8
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pro Forma
Combined Financial Information
The following unaudited pro forma combined financial information
for the three and nine months ended September 30, 2007
gives effect to the Arrow merger as if it was completed at the
beginning of the period.
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
(Dollars in thousands, except per share amounts)
|
|
|
Net revenue
|
|
$
|
591,592
|
|
|
$
|
1,740,214
|
|
Loss from continuing operations
|
|
$
|
(72,751
|
)
|
|
$
|
(83,688
|
)
|
Net loss
|
|
$
|
(66,563
|
)
|
|
$
|
(6,442
|
)
|
Basic loss per common share:
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(1.85
|
)
|
|
$
|
(2.13
|
)
|
Net loss
|
|
$
|
(1.69
|
)
|
|
$
|
(0.16
|
)
|
Diluted loss per common share:
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(1.85
|
)
|
|
$
|
(2.13
|
)
|
Net loss
|
|
$
|
(1.69
|
)
|
|
$
|
(0.16
|
)
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
|
|
|
39,368
|
|
|
|
39,207
|
|
Diluted
|
|
|
39,368
|
|
|
|
39,207
|
|
The unaudited pro forma combined financial information presented
above includes special charges in the nine month period of
$35.8 million of inventory
step-up,
$30.0 million for in-process research and development
write-off that is charged to expense as of the date of the
combination and $1.0 million financing costs paid to third
parties in connection with the amendment of certain outstanding
notes.
Integration
of Arrow
In connection with the acquisition of Arrow, the Company
formulated a plan related to the future integration of Arrow and
the Companys Medical businesses. The integration plan
focuses on the closure of Arrow corporate functions and the
consolidation of manufacturing, sales, marketing and
distribution functions in North America, Europe and Asia. The
Company does not expect the finalization of these programs to
result in a material adjustment to the estimated costs to
implement the plan.
The Company initially recognized $31.6 million as a
liability assumed in the acquisition of Arrow for the estimated
costs to carry out the integration plan, and included this
amount in the allocation of the purchase price. Of this amount,
$18.4 million relates to employee termination costs,
$3.6 million to facility closure costs, and
$9.6 million to termination of certain distribution
agreements and other actions. The Company continues to evaluate
and adjust the liabilities relating to the Arrow integration
plan. The activity, including changes in estimates to the
integration cost accrual from December 31, 2007 through
September 28, 2008 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee
|
|
|
|
|
|
Contract
|
|
|
Other
|
|
|
|
|
|
|
Termination
|
|
|
Facility
|
|
|
Termination
|
|
|
Restructuring
|
|
|
|
|
|
|
Benefits
|
|
|
Closure Costs
|
|
|
Costs
|
|
|
Costs
|
|
|
Total
|
|
|
|
(Dollars in millions)
|
|
|
Balance at December 31, 2007
|
|
$
|
14.8
|
|
|
$
|
3.6
|
|
|
$
|
9.6
|
|
|
$
|
|
|
|
$
|
28.0
|
|
Cash payments
|
|
|
(5.3
|
)
|
|
|
(0.2
|
)
|
|
|
(1.5
|
)
|
|
|
(0.2
|
)
|
|
|
(7.2
|
)
|
Adjustments to reserve
|
|
|
(0.4
|
)
|
|
|
(2.5
|
)
|
|
|
1.9
|
|
|
|
1.4
|
|
|
|
0.4
|
|
Foreign currency translation
|
|
|
0.3
|
|
|
|
0.2
|
|
|
|
0.5
|
|
|
|
0.1
|
|
|
|
1.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 28, 2008
|
|
$
|
9.4
|
|
|
$
|
1.1
|
|
|
$
|
10.5
|
|
|
$
|
1.3
|
|
|
$
|
22.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
It is anticipated that a majority of the balance of these costs
will be charged to the reserve in 2008 and 2009; however, it is
currently projected that the costs for some portions of the
manufacturing integration will be charged to the reserve through
the third quarter of 2010.
In conjunction with the plan for the integration of Arrow and
the Companys Medical businesses, the Company expects to
take actions that affect employees and facilities of Teleflex.
This aspect of the integration plan is explained in Note 4
Restructuring and such costs incurred will be
charged to earnings and included in restructuring and
impairment charges within the condensed consolidated
statement of operations.
Acquisition
of Nordisk Aviation Products
In November 2007, the company acquired Nordisk Aviation Products
a.s. (Nordisk), a world leader in developing, supplying and
servicing containers and pallets for air cargo, for
approximately $27.8 million, net of cash acquired. The
results of Nordisk are included in the Companys Aerospace
Segment. Revenues for the three and nine month periods ending
September 28, 2008 were $14.1 million and
$40.5 million, respectively.
The amounts recognized in restructuring and impairment charges
for the three and nine month periods ended September 28,
2008 and September 30, 2007 consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
2007 Arrow integration program
|
|
$
|
432
|
|
|
$
|
|
|
|
$
|
11,212
|
|
|
$
|
|
|
2006 restructuring program
|
|
|
38
|
|
|
|
1,107
|
|
|
|
705
|
|
|
|
2,027
|
|
Aerospace Segment restructuring activity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
2004 restructuring and divestiture program
|
|
|
|
|
|
|
73
|
|
|
|
|
|
|
|
678
|
|
Impairment charges
|
|
|
|
|
|
|
3,757
|
|
|
|
|
|
|
|
3,757
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and impairment charges
|
|
$
|
470
|
|
|
$
|
4,937
|
|
|
$
|
11,917
|
|
|
$
|
6,459
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
Arrow Integration Program
In connection with the acquisition of Arrow, the Company
formulated a plan related to the future integration of Arrow and
the Companys Medical businesses. The integration plan
focuses on the closure of Arrow corporate functions and the
consolidation of manufacturing, sales, marketing and
distribution functions in North America, Europe and Asia. Costs
related to actions that affect employees and facilities of Arrow
have been included in the allocation of the purchase price of
Arrow. Costs related to actions that affect employees and
facilities of Teleflex are charged to earnings and included in
restructuring and impairment charges within the
consolidated statement of operations. As of September 28,
2008, the Company estimates that the aggregate of future
restructuring and impairment charges that it will incur are
approximately $22.0 $25.0 million in 2008 and
2009 in connection with the Arrow integration plan. Of this
amount, $10.3 $11.3 million relates to employee
termination costs, $10.5 $11.5 million relates
to costs associated with the termination of leases and certain
distribution agreements and $1.2 $2.2 million
relates to other restructuring costs.
10
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The charges associated with the 2007 Arrow integration program
which are included in restructuring and impairment charges for
the three and nine month periods ended September 28, 2008
were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28, 2008
|
|
|
September 28, 2008
|
|
|
|
Medical
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
44
|
|
|
$
|
9,882
|
|
Contract termination costs
|
|
|
63
|
|
|
|
869
|
|
Other restructuring costs
|
|
|
325
|
|
|
|
461
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
432
|
|
|
$
|
11,212
|
|
|
|
|
|
|
|
|
|
|
At September 28, 2008, the accrued liability associated
with the 2007 Arrow integration program consisted of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
September 28,
|
|
|
|
2007
|
|
|
Accruals
|
|
|
Payments
|
|
|
Translation
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
606
|
|
|
$
|
9,882
|
|
|
$
|
(4,767
|
)
|
|
$
|
314
|
|
|
$
|
6,035
|
|
Contract termination costs
|
|
|
|
|
|
|
869
|
|
|
|
(622
|
)
|
|
|
14
|
|
|
|
261
|
|
Other restructuring costs
|
|
|
|
|
|
|
461
|
|
|
|
(215
|
)
|
|
|
(13
|
)
|
|
|
233
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
606
|
|
|
$
|
11,212
|
|
|
$
|
(5,604
|
)
|
|
$
|
315
|
|
|
$
|
6,529
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
Restructuring Program
In June 2006, the Company began certain restructuring
initiatives that affected all three of the Companys
reporting segments. These initiatives involved the consolidation
of operations and a related reduction in workforce at several of
the Companys facilities in Europe and North America. The
Company determined to undertake these initiatives to improve
operating performance and to better leverage the Companys
existing resources.
For the three and nine month periods ended September 28,
2008 and September 30, 2007, the charges, including changes
in estimates, associated with the 2006 restructuring program by
segment that are included in restructuring and impairment
charges were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28, 2008
|
|
|
September 28, 2008
|
|
|
|
Medical
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
|
|
|
$
|
589
|
|
Contract termination costs
|
|
|
38
|
|
|
|
116
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
38
|
|
|
$
|
705
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
September 30, 2007
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
|
|
|
$
|
61
|
|
|
$
|
50
|
|
|
$
|
111
|
|
Contract termination costs
|
|
|
|
|
|
|
320
|
|
|
|
48
|
|
|
|
368
|
|
Asset impairments
|
|
|
|
|
|
|
|
|
|
|
361
|
|
|
|
361
|
|
Other restructuring costs
|
|
|
257
|
|
|
|
10
|
|
|
|
|
|
|
|
267
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
257
|
|
|
$
|
391
|
|
|
$
|
459
|
|
|
$
|
1,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
|
September 30, 2007
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
|
|
|
$
|
775
|
|
|
$
|
129
|
|
|
$
|
904
|
|
Contract termination costs
|
|
|
|
|
|
|
411
|
|
|
|
48
|
|
|
|
459
|
|
Asset impairments
|
|
|
|
|
|
|
|
|
|
|
361
|
|
|
|
361
|
|
Other restructuring costs
|
|
|
257
|
|
|
|
46
|
|
|
|
|
|
|
|
303
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
257
|
|
|
$
|
1,232
|
|
|
$
|
538
|
|
|
$
|
2,027
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination benefits are comprised of severance-related payments
for all employees terminated in connection with the 2006
restructuring program. Contract termination costs relate
primarily to the termination of leases in conjunction with the
consolidation of facilities. Other restructuring costs include
expenses primarily related to the consolidation of manufacturing
operations and the reorganization of administrative functions.
At September 28, 2008, the accrued liability associated
with the 2006 restructuring program consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
September 28,
|
|
|
|
2007
|
|
|
Accruals
|
|
|
Payments
|
|
|
Translation
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
1,217
|
|
|
$
|
589
|
|
|
$
|
(1,623
|
)
|
|
$
|
(38
|
)
|
|
$
|
145
|
|
Contract termination costs
|
|
|
561
|
|
|
|
116
|
|
|
|
(325
|
)
|
|
|
|
|
|
|
352
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,778
|
|
|
$
|
705
|
|
|
$
|
(1,948
|
)
|
|
$
|
(38
|
)
|
|
$
|
497
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The termination benefits set forth above are payable within
twelve months.
As of September 28, 2008, the Company expects to incur
future restructuring expenses related to contract terminations
of approximately $228 thousand.
2004
Restructuring and Divestiture Program
During the fourth quarter of 2004, the Company announced and
commenced implementation of a restructuring and divestiture
program designed to improve future operating performance and
position the Company for future earnings growth. Actions taken
under the program included exiting or divesting of non-core or
low performing businesses, consolidating manufacturing
operations and reorganizing administrative functions to enable
businesses to share services.
No costs were incurred during the three and nine month periods
ending September 28, 2008. For the three and nine month
periods ended September 30, 2007 the costs, including
changes in estimates, associated with the 2004 restructuring and
divestiture program were incurred by the Companys Medical
Segment and are included in restructuring and impairment charges
as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30, 2007
|
|
|
September 30, 2007
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
(34
|
)
|
|
$
|
(34
|
)
|
Other restructuring costs
|
|
|
107
|
|
|
|
712
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
73
|
|
|
$
|
678
|
|
|
|
|
|
|
|
|
|
|
12
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Other restructuring costs include expenses primarily related to
the consolidation of manufacturing operations and the
reorganization of administrative functions.
At September 28, 2008, the accrued liability associated
with the 2004 restructuring program consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accruals and
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Changes in
|
|
|
|
|
|
September 28,
|
|
|
|
2007
|
|
|
Estimates
|
|
|
Payments
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
25
|
|
|
$
|
|
|
|
$
|
(25
|
)
|
|
$
|
|
|
Contract termination costs
|
|
|
1,187
|
|
|
|
|
|
|
|
(493
|
)
|
|
|
694
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,212
|
|
|
$
|
|
|
|
$
|
(518
|
)
|
|
$
|
694
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 28, 2008 the Company does not expect to
incur additional restructuring expenses associated with the 2004
restructuring and divestiture program.
Impairment
Charges
During October of 2007, the Company signed a letter of intent to
sell its ownership interest in one of its variable interest
entities. Based on the agreed selling price, the Company
determined that the carrying value of the entitys
long-lived assets was impaired and recorded a charge of
approximately $3.8 million which was included in
restructuring and impairment charges in 2007.
Inventories consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
September 28,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Raw materials
|
|
$
|
202,417
|
|
|
$
|
179,560
|
|
Work-in-process
|
|
|
66,641
|
|
|
|
61,912
|
|
Finished goods
|
|
|
200,792
|
|
|
|
213,631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
469,850
|
|
|
|
455,103
|
|
Less: Inventory reserve
|
|
|
(39,670
|
)
|
|
|
(35,915
|
)
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
$
|
430,180
|
|
|
$
|
419,188
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 6
|
Goodwill
and other intangible assets
|
Changes in the carrying amount of goodwill, by operating
segment, for the nine months ended September 28, 2008 are
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Commercial
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Goodwill at December 31, 2007
|
|
$
|
1,452,894
|
|
|
$
|
6,317
|
|
|
$
|
43,045
|
|
|
$
|
1,502,256
|
|
Adjustment to acquisition balance
sheet(1)
|
|
|
1,839
|
|
|
|
|
|
|
|
|
|
|
|
1,839
|
|
Translation adjustment
|
|
|
(5,433
|
)
|
|
|
|
|
|
|
(904
|
)
|
|
|
(6,337
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill at September 28, 2008
|
|
$
|
1,449,300
|
|
|
$
|
6,317
|
|
|
$
|
42,141
|
|
|
$
|
1,497,758
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 3 Acquisitions |
13
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Carrying Amount
|
|
|
Accumulated Amortization
|
|
|
|
September 28,
|
|
|
December 31,
|
|
|
September 28,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Customer lists
|
|
$
|
563,868
|
|
|
$
|
568,701
|
|
|
$
|
42,483
|
|
|
$
|
23,643
|
|
Intellectual property
|
|
|
225,448
|
|
|
|
229,325
|
|
|
|
50,037
|
|
|
|
39,100
|
|
Distribution rights
|
|
|
28,139
|
|
|
|
28,139
|
|
|
|
17,157
|
|
|
|
16,437
|
|
Trade names
|
|
|
338,784
|
|
|
|
338,834
|
|
|
|
761
|
|
|
|
311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,156,239
|
|
|
$
|
1,164,999
|
|
|
$
|
110,438
|
|
|
$
|
79,491
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense related to intangible assets was
approximately $11.5 million and $3.2 million for the
three months ended and $35.1 million and $8.9 million
for the nine months ended September 28, 2008 and
September 30, 2007, respectively. Estimated annual
amortization expense for each of the five succeeding years is as
follows (dollars in thousands):
|
|
|
|
|
2008
|
|
$
|
46,700
|
|
2009
|
|
|
46,400
|
|
2010
|
|
|
46,300
|
|
2011
|
|
|
46,000
|
|
2012
|
|
|
44,800
|
|
|
|
Note 7
|
Comprehensive
income
|
The following table summarizes the components of comprehensive
income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Net income (loss)
|
|
$
|
42,319
|
|
|
$
|
(57,036
|
)
|
|
$
|
100,205
|
|
|
$
|
81,099
|
|
Net unrealized gains (losses) on qualifying cash flow hedges
|
|
|
107
|
|
|
|
(865
|
)
|
|
|
(61
|
)
|
|
|
1,542
|
|
Changes in pension and postretirement obligations
|
|
|
(2,925
|
)
|
|
|
514
|
|
|
|
(2,399
|
)
|
|
|
1,734
|
|
Pension curtailment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,484
|
|
Cumulative translation adjustment
|
|
|
(38,963
|
)
|
|
|
23,171
|
|
|
|
(14,113
|
)
|
|
|
37,758
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss)
|
|
$
|
538
|
|
|
$
|
(34,216
|
)
|
|
$
|
83,632
|
|
|
$
|
123,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 8
|
Changes
in shareholders equity
|
Set forth below is a reconciliation of the Companys issued
common shares:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Shares in thousands)
|
|
|
Common shares, beginning of period
|
|
|
41,932
|
|
|
|
41,694
|
|
|
|
41,794
|
|
|
|
41,364
|
|
Shares issued under compensation plans
|
|
|
52
|
|
|
|
92
|
|
|
|
190
|
|
|
|
422
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares, end of period
|
|
|
41,984
|
|
|
|
41,786
|
|
|
|
41,984
|
|
|
|
41,786
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On June 14, 2007, the Companys Board of Directors
authorized the repurchase of up to $300 million of
outstanding Company common stock. Repurchases of Company stock
under the Board authorization may be made from time to time in
the open market and may include privately-negotiated
transactions as market conditions warrant and subject to
regulatory considerations. The stock repurchase program has no
expiration date, and the Companys ability to execute on
the program will depend on, among other factors, cash
requirements for acquisitions, cash generation from operations,
debt repayment obligations, market conditions and regulatory
requirements. In addition, under the senior loan agreements
entered into on October 1, 2007, the Company is subject to
certain restrictions relating to its ability to repurchase
shares in the event the Companys consolidated leverage
ratio exceeds certain levels, which may further limit the
Companys ability to repurchase shares under this Board
authorization. Through September 28, 2008, no shares have
been purchased under this Board authorization.
Basic earnings per share is computed by dividing net income by
the weighted average number of common shares outstanding during
the period. Diluted earnings per share is computed in the same
manner except that the weighted average number of shares is
increased for dilutive securities. The difference between basic
and diluted weighted average common shares results from the
assumption that dilutive share-based payment awards were
exercised or vested at the beginning of the period. A
reconciliation of basic to diluted weighted average shares
outstanding is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Shares in thousands)
|
|
|
Basic
|
|
|
39,645
|
|
|
|
39,368
|
|
|
|
39,553
|
|
|
|
39,207
|
|
Dilutive shares assumed issued
|
|
|
325
|
|
|
|
|
|
|
|
284
|
|
|
|
431
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
39,970
|
|
|
|
39,368
|
|
|
|
39,837
|
|
|
|
39,638
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average stock options that were anti-dilutive and
therefore not included in the calculation of earnings per share
were approximately 666 thousand and 908 thousand for the three
and nine month periods ended September 28, 2008 and
approximately 666 thousand and 442 thousand for the three and
nine month periods ended September 30, 2007, respectively.
|
|
Note 9
|
Stock
compensation plans
|
The Company has two stock-based compensation plans under which
equity-based awards may be made. The Companys 2000 Stock
Compensation Plan (the 2000 plan) provides for the
granting of incentive and non-qualified stock options and
restricted stock units to directors, officers and key employees.
Under the 2000 plan, the Company is authorized to issue up to
4 million shares of common stock, but no more than 800,000
of those shares may be issued as restricted stock. Options
granted under the 2000 plan have an exercise price equal to the
average of the high and low sales prices of the Companys
common stock on the date of the grant, rounded to the nearest
$0.25.
15
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Generally, options granted under the 2000 plan are exercisable
three to five years after the date of the grant and expire no
more than ten years after the grant. Outstanding restricted
stock units generally vest in one to three years. During the
first nine months of 2008, the Company granted incentive and
non-qualified options to purchase 381,881 shares of common
stock and granted restricted stock units representing
154,468 shares of common stock under the 2000 plan.
The Companys 2008 Stock Incentive Plan (the 2008
plan) provides for the granting of various types of
equity-based awards to directors, officers and key employees.
These awards include incentive and non-qualified stock options,
stock appreciation rights, stock awards and other stock-based
awards. Under the 2008 plan, the Company is authorized to issue
up to 2.5 million shares of common stock, but grants of
awards other than stock options and stock appreciation rights
may not exceed 875,000 shares. Options granted under the
2008 plan will have an exercise price equal to the closing price
of the Companys common stock on the date of grant. The
2008 plan was approved by the Companys stockholders on
May 1, 2008 at the Companys annual meeting of
stockholders. During the first nine months of 2008, no awards
have been granted under the 2008 plan.
|
|
Note 10
|
Pension
and other postretirement benefits
|
The Company has a number of defined benefit pension and
postretirement plans covering eligible U.S. and
non-U.S. employees.
The defined benefit pension plans are noncontributory. The
benefits under these plans are based primarily on years of
service and employees pay near retirement. The benefits
under the U.S. defined benefit pension plans are no longer
available to new employees with certain exceptions. The
Companys funding policy for U.S. plans is to
contribute annually, at a minimum, amounts required by
applicable laws and regulations. Obligations under
non-U.S. plans
are systematically provided for by depositing funds with
trustees or by book reserves.
The Company and certain of its subsidiaries provide medical,
dental and life insurance benefits to pensioners and survivors.
The associated plans are unfunded and approved claims are paid
from Company funds.
Net benefit cost of pension and postretirement benefit plans
consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Service cost
|
|
$
|
941
|
|
|
$
|
905
|
|
|
$
|
486
|
|
|
$
|
106
|
|
|
$
|
3,597
|
|
|
$
|
2,714
|
|
|
$
|
980
|
|
|
$
|
318
|
|
Interest cost
|
|
|
4,599
|
|
|
|
2,974
|
|
|
|
1,170
|
|
|
|
416
|
|
|
|
13,910
|
|
|
|
8,920
|
|
|
|
2,665
|
|
|
|
1,246
|
|
Expected return on plan assets
|
|
|
(5,804
|
)
|
|
|
(3,367
|
)
|
|
|
|
|
|
|
|
|
|
|
(17,446
|
)
|
|
|
(10,099
|
)
|
|
|
|
|
|
|
|
|
Net amortization and deferral
|
|
|
446
|
|
|
|
614
|
|
|
|
266
|
|
|
|
281
|
|
|
|
1,388
|
|
|
|
1,842
|
|
|
|
797
|
|
|
|
845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net benefit cost
|
|
$
|
182
|
|
|
$
|
1,126
|
|
|
$
|
1,922
|
|
|
$
|
803
|
|
|
$
|
1,449
|
|
|
$
|
3,377
|
|
|
$
|
4,442
|
|
|
$
|
2,409
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 11
|
Fair
Value Measurement
|
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurements, (SFAS 157), which is
effective for fiscal years beginning after November 15,
2007 and for interim periods within those years. This statement
defines fair value, establishes a framework for measuring fair
value and expands the related disclosure requirements. This
statement applies under other accounting pronouncements that
require or permit fair value measurements. The statement
indicates, among other things, that a fair value measurement
assumes that the transaction to sell an asset or transfer a
liability occurs in the principal market for the asset or
liability or, in the absence of a principal market, the most
advantageous market for the asset or liability. SFAS 157
defines fair value based upon an exit price model.
16
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Relative to SFAS 157, the FASB issued
FSP 157-1,
157-2 and
157-3.
FSP 157-1
amends SFAS 157 to exclude SFAS No. 13,
Accounting for Leases, (SFAS 13) and its
related interpretive accounting pronouncements that address
leasing transactions, while
FSP 157-2
delays the effective date of the application of SFAS 157 to
fiscal years beginning after November 15, 2008 for all
nonfinancial assets and nonfinancial liabilities that are
recognized or disclosed at fair value in the financial
statements on a nonrecurring basis. Non-recurring nonfinancial
assets and nonfinancial liabilities include those measured at
fair value in goodwill impairment testing, indefinite lived
intangible assets measured at fair value for impairment testing,
asset retirement obligations initially measured at fair value,
and those assets and liabilities initially measured at fair
value in a business combination.
FSP 157-3
clarifies the application of SFAS 157 in determining the
fair value of a financial asset when the market for that
financial asset is not active. The Companys financial
assets are traded in active markets using both Level 1 and
Level 2 (described below) inputs that are not adjusted by
the Company in determining fair value. In measuring fair value
including the key considerations clarified in FSP 157-3, we
have reconfirmed our initial determination that financial assets
are comprised of both Level 1 and Level 2 inputs in
active markets.
The Company adopted SFAS 157 for financial assets and
financial liabilities as of January 1, 2008, in accordance
with the provisions of SFAS 157 and the related guidance of
FSP 157-1,
FSP 157-2
and
FSP 157-3.
The adoption did not have an impact on the Companys
financial position and results of operations. The Company
endeavors to utilize the best available information in measuring
fair value. The Company has determined the fair value of its
financial assets based on Level 1 and Level 2 inputs
and the fair value of its financial liabilities based on
Level 2 inputs in accordance with the fair value hierarchy
described as follows:
Valuation
Hierarchy
SFAS 157 establishes a valuation hierarchy of the inputs
used to measure fair value. This hierarchy prioritizes the
inputs into three broad levels as follows:
Level 1 inputs quoted prices (unadjusted) in
active markets for identical assets or liabilities that the
Company has ability to access at the measurement date.
Level 2 inputs inputs other than quoted prices
included within Level 1 that are observable for the asset or
liability, either directly or indirectly. If the asset or
liability has a specified (contractual) term, a Level 2
input must be observable for substantially the full term of the
asset or liability. Level 2 inputs include:
1. Quoted prices for similar assets or liabilities in
active markets.
2. Quoted prices for identical or similar assets or
liabilities in markets that are not active or there are few
transactions.
3. Inputs other than quoted prices that are observable for
the asset or liability.
4. Inputs that are derived principally from or corroborated
by observable market data by correlation or other means.
Level 3 inputs unobservable inputs for the
asset or liability. Unobservable inputs may be used to measure
fair value only when observable inputs are not available.
Unobservable inputs reflect the Companys assumptions about
the assumptions market participants would use in pricing the
asset or liability in achieving the fair value measurement
objective of an exit price perspective.
A financial asset or liabilitys classification within the
hierarchy is determined based on the lowest level input that is
significant to the fair value measurement.
17
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table provides the financial assets and
liabilities carried at fair value measured on a recurring basis
as of September 28, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Carrying
|
|
|
Quoted prices in
|
|
|
Significant other
|
|
|
Significant
|
|
|
|
Value at
|
|
|
active markets
|
|
|
observable inputs
|
|
|
unobservable inputs
|
|
|
|
September 28, 2008
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
|
|
(Dollars in thousands)
|
|
|
Deferred compensation assets
|
|
$
|
3,272
|
|
|
$
|
3,272
|
|
|
$
|
|
|
|
$
|
|
|
Derivative assets
|
|
$
|
578
|
|
|
$
|
|
|
|
$
|
578
|
|
|
$
|
|
|
Derivative liabilities
|
|
$
|
17,873
|
|
|
$
|
|
|
|
$
|
17,873
|
|
|
$
|
|
|
Valuation
Techniques
The Companys financial assets valued based upon
Level 1 inputs are comprised of investments in marketable
securities held in Rabbi Trusts which are used to pay benefits
under certain deferred compensation plan benefits. Under these
deferred compensation plans, participants designate investment
options to serve as the basis for measurement of the notional
value of their accounts. The investment assets of the rabbi
trust are valued using quoted market prices multiplied by the
number of shares held in the trust.
The Companys financial assets valued based upon
Level 2 inputs are comprised of foreign currency forward
contracts. The Companys financial liabilities valued based
upon Level 2 inputs are comprised of an interest rate swap
contract and foreign currency forward contracts. The Company has
taken into account the creditworthiness of the counterparties in
measuring fair value. The Company uses forward rate contracts to
manage currency transaction exposure and interest rate swaps to
manage exposure to interest rate changes. The fair value of the
interest rate swap contract is developed from market-based
inputs under the income approach using cash flows discounted at
relevant market interest rates. The fair value of the foreign
currency forward exchange contracts represents the amount
required to enter into offsetting contracts with similar
remaining maturities based on quoted market prices.
|
|
Note 12
|
Commitments
and contingent liabilities
|
Product warranty liability: The Company
warrants to the original purchaser of certain of its products
that it will, at its option, repair or replace, without charge,
such products if they fail due to a manufacturing defect.
Warranty periods vary by product. The Company has recourse
provisions for certain products that would enable recovery from
third parties for amounts paid under the warranty. The Company
accrues for product warranties when, based on available
information, it is probable that customers will make claims
under warranties relating to products that have been sold, and a
reasonable estimate of the costs (based on historical claims
experience relative to sales) can be made. Set forth below is a
reconciliation of the Companys estimated product warranty
liability for the nine months ended September 28, 2008
(dollars in thousands):
|
|
|
|
|
Balance December 31, 2007
|
|
$
|
19,981
|
|
Accruals for warranties issued in 2008
|
|
|
8,351
|
|
Settlements (cash and in kind)
|
|
|
(10,058
|
)
|
Accruals related to pre-existing warranties
|
|
|
220
|
|
Effect of translation
|
|
|
(422
|
)
|
|
|
|
|
|
Balance September 28, 2008
|
|
$
|
18,072
|
|
|
|
|
|
|
Operating leases: The Company uses various
leased facilities and equipment in its operations. The terms for
these leased assets vary depending on the applicable lease
agreement. In connection with these operating leases, the
Company had residual value guarantees in the amount of
approximately $1.9 million at September 28, 2008. The
Companys future payments under these leases cannot exceed
the minimum rent obligation plus the residual value guarantee
amount. The guarantee amounts are tied to the unamortized lease
values of the assets under lease, and are
18
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
due should the Company decide neither to renew these leases, nor
to exercise its purchase option. At September 28, 2008, the
Company had no liabilities recorded for these obligations. Any
residual value guarantee amounts paid to the lessor may be
recovered by the Company from the sale of the assets to a third
party.
Accounts receivable securitization
program: The Company uses an accounts receivable
securitization program to gain access to enhanced credit markets
and reduce financing costs. As currently structured, the Company
sells certain trade receivables on a non-recourse basis to a
consolidated special purpose entity which in turn sells
interests in those receivables to a commercial paper conduit.
The conduit issues notes secured by those interests to third
party investors. The assets of the special purpose entity are
not available to satisfy our obligations. The total amount of
accounts receivable held by the special purpose entity at
September 28, 2008 and December 31, 2007 were
$147.6 million and $124.3 million, respectively. The
special purpose entity has received cash consideration of
$39.7 million for the interests in the accounts receivable
it has sold to the commercial paper conduit at each of
September 28, 2008 and December 31, 2007, which
amounts were removed from the consolidated balance sheet at such
dates in accordance with SFAS 140, Accounting for
Transfers and Servicing of Financial Assets and Extinguishments
of Liabilities.
Environmental: The Company is subject to
contingencies as a result of environmental laws and regulations
that in the future may require the Company to take further
action to correct the effects on the environment of prior
disposal practices or releases of chemical or petroleum
substances by the Company or other parties. Much of this
liability results from the U.S. Comprehensive Environmental
Response, Compensation and Liability Act (CERCLA),
often referred to as Superfund, the U.S. Resource
Conservation and Recovery Act (RCRA) and similar
state laws. These laws require the Company to undertake certain
investigative and remedial activities at sites where the Company
conducts or once conducted operations or at sites where
Company-generated waste was disposed.
Remediation activities vary substantially in duration and cost
from site to site. These activities, and their associated costs,
depend on the mix of unique site characteristics, evolving
remediation technologies, diverse regulatory agencies and
enforcement policies, as well as the presence or absence of
other potentially responsible parties. At September 28,
2008, the Companys condensed consolidated balance sheet
included an accrued liability of approximately $8.6 million
relating to these matters. Considerable uncertainty exists with
respect to these costs and, if adverse changes in circumstances
occur, potential liability may exceed the amount accrued as of
September 28, 2008. The time frame over which the accrued
amounts may be paid out, based on past history, is estimated to
be
15-20 years.
Regulatory matters: On October 11, 2007,
the Companys subsidiary, Arrow International, Inc.
(Arrow), received a corporate warning letter from
the U.S. Food and Drug Administration (FDA). The letter
cites three site-specific warning letters issued by the FDA in
2005 and subsequent inspections performed from June 2005 to
February 2007 at Arrows facilities in the United States.
The letter expresses concerns with Arrows quality systems,
including complaint handling, corrective and preventive action,
process and design validation, inspection and training
procedures. It also advises that Arrows corporate-wide
program to evaluate, correct and prevent quality system issues
has been deficient. Limitations on pre-market approvals and
certificates of foreign goods had previously been imposed on
Arrow based on prior inspections and the corporate warning
letter does not impose additional sanctions that are expected to
have a material financial impact on the Company.
In connection with its acquisition of Arrow, completed on
October 1, 2007, the Company developed an integration plan
that includes the commitment of significant resources to correct
these previously-identified regulatory issues and further
improve overall quality systems. Senior management officials
from the Company have met with FDA representatives, and a
comprehensive written corrective action plan was presented to
FDA in late 2007. The Company has begun implementing its
corrective action plan, which it expects to complete, for most
facilities and procedures, by the end of 2008.
19
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
While the Company believes it can remediate these issues, there
can be no assurances regarding the length of time or
expenditures required to resolve these issues to the
satisfaction of the FDA. If the Companys remedial actions
are not satisfactory to the FDA, the Company may have to devote
additional financial and human resources to its efforts, and the
FDA may take further regulatory actions against the Company,
including, but not limited to, seizing its product inventory,
obtaining a court injunction against further marketing of the
Companys products or assessing civil monetary penalties.
In June 2008, HM Revenue and Customs (HMRC) assessed
Airfoil Technologies International UK Limited
(ATI-UK), a consolidated United Kingdom venture in
which the Company has a 60% economic interest, approximately
$13 million for customs duty for the period from
July 1, 2005 through March 31, 2008. HMRC had
previously assessed ATI-UK approximately $1 million for
customs duty for the first and second quarters of 2004.
Additionally, for the above periods, ATI-UK was assessed a value
added tax (VAT) of approximately $93 million,
for which HMRC has advised ATI-UK that, to the extent it is due
and payable, it has until March 2010 to fully recover such VAT.
The assessments were imposed because HMRC concluded that ATI-UK
did not provide the necessary documentation for which reliance
on Inland Processing Relief status (duty and VAT) was claimed by
ATI-UK.
ATI-UK has filed appeals and been granted hardship applications
(to avoid payment of the assessment while the appeal is pending)
regarding each of the assessments. ATI-UK has provided certain
documentation to HMRC and is continuing to assemble
documentation for submission to HMRC and intends to vigorously
contest these assessments. In the event ATI-UK is not successful
in a favorable resolution of the assessments, such outcome would
have a material adverse effect on the business of ATI-UK. The
Company has a net investment in ATI-UK of approximately
$12 million.
Litigation: The Company is a party to various
lawsuits and claims arising in the normal course of business.
These lawsuits and claims include actions involving product
liability, intellectual property, employment and environmental
matters. Based on information currently available, advice of
counsel, established reserves and other resources, the Company
does not believe that any such actions are likely to be,
individually or in the aggregate, material to its business,
financial condition, results of operations or liquidity.
However, in the event of unexpected further developments, it is
possible that the ultimate resolution of these matters, or other
similar matters, if unfavorable, may be materially adverse to
the Companys business, financial condition, results of
operations or liquidity. Legal costs such as outside counsel
fees and expenses are charged to expense in the period incurred.
Other: The Company has various purchase
commitments for materials, supplies and items of permanent
investment incident to the ordinary conduct of business. On
average, such commitments are not at prices in excess of current
market.
20
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 13
|
Business
segment information
|
Information about continuing operations by business segment is
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
367,327
|
|
|
$
|
227,825
|
|
|
$
|
1,125,719
|
|
|
$
|
681,142
|
|
Aerospace
|
|
|
126,927
|
|
|
|
113,747
|
|
|
|
385,765
|
|
|
|
331,351
|
|
Commercial
|
|
|
101,628
|
|
|
|
116,990
|
|
|
|
313,003
|
|
|
|
338,726
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment net revenues
|
|
|
595,882
|
|
|
|
458,562
|
|
|
|
1,824,487
|
|
|
|
1,351,219
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
71,388
|
|
|
|
50,448
|
|
|
|
212,952
|
|
|
|
142,275
|
|
Aerospace
|
|
|
16,786
|
|
|
|
7,544
|
|
|
|
45,912
|
|
|
|
32,174
|
|
Commercial
|
|
|
7,067
|
|
|
|
2,304
|
|
|
|
19,374
|
|
|
|
18,010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating
profit(1)
|
|
|
95,241
|
|
|
|
60,296
|
|
|
|
278,238
|
|
|
|
192,459
|
|
Less: Corporate expenses
|
|
|
10,379
|
|
|
|
9,140
|
|
|
|
32,742
|
|
|
|
32,206
|
|
Net (gain)/loss on sales of businesses and assets
|
|
|
|
|
|
|
(207
|
)
|
|
|
18
|
|
|
|
1,121
|
|
Restructuring and impairment charges
|
|
|
470
|
|
|
|
4,937
|
|
|
|
11,917
|
|
|
|
6,459
|
|
Minority interest
|
|
|
(9,627
|
)
|
|
|
(7,200
|
)
|
|
|
(25,779
|
)
|
|
|
(21,016
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest, taxes and
minority interest
|
|
$
|
94,019
|
|
|
$
|
53,626
|
|
|
$
|
259,340
|
|
|
$
|
173,689
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Segment operating profit includes a segments net revenues
reduced by its materials, labor and other product costs along
with the segments selling, engineering and administrative
expenses and minority interest. Unallocated corporate expenses,
(gain) loss on sales of assets, restructuring and impairment
charges, interest income and expense and taxes on income are
excluded from the measure. |
|
|
Note 14
|
Divestiture-Related
Activities
|
As dispositions occur in the normal course of business, gains or
losses on the sale of such businesses are recognized in the
income statement line item Net (gain) loss on sales of
businesses and assets.
Net (gain) loss on sales of businesses and assets
consists of the following for the three and nine month
periods ended September 28, 2008 and September 30,
2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Net (gain) loss on sales of businesses and assets
|
|
$
|
|
|
|
$
|
(207
|
)
|
|
$
|
18
|
|
|
$
|
1,121
|
|
During the first quarter of 2008, the Company incurred $18
thousand of additional expenses in connection with the
completion of the sale of its ownership interest in one of its
variable interest entities.
21
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
During the first nine months of 2007, the Company sold a
building which it had classified as held for sale and realized a
pre-tax gain of $793 thousand and sold a business in the Medical
Segment and realized a pre-tax loss of $1.9 million.
Assets
Held for Sale
Assets held for sale at September 28, 2008 consists of two
buildings that the Company is actively marketing. Assets held
for sale at December 31, 2007 consisted of three buildings.
The Company sold a building in the second quarter of 2008 for an
amount equal to its book value.
Discontinued
Operations
On December 27, 2007 the Company completed the sale of its
business units that design and manufacture automotive and
industrial driver controls, motion systems and fluid handling
systems (the GMS businesses) to Kongsberg Automotive
Holding for $560 million in cash. The sale price is subject
to adjustment based upon the working capital of the business
units included in the sale as of December 27, 2007. The
Companys condensed consolidated statement of income for
the three and nine month periods ended September 30, 2007
has been retrospectively adjusted to reflect these operations as
discontinued. The divested GMS businesses were all part of the
Companys Commercial Segment.
In the second quarter of 2008, the Company refined its estimates
for the post-closing adjustments based on the provisions of the
Purchase Agreement. Also during the second quarter of 2008, the
Company recorded a charge for the settlement of a contingency
related to the sale of the GMS businesses. These activities
resulted in a decrease in the gain on sale of the GMS businesses
and are reported as a loss from discontinued operations of
$2.8 million, net of taxes of $2.0 million for the
nine months ended September 28, 2008.
On June 29, 2007 the Company completed the sale of Teleflex
Aerospace Manufacturing Group (TAMG), a
precision-machined components business in the Aerospace Segment
for $133.9 million in cash and realized a pre-tax gain of
$75.2 million.
The results of these discontinued operations for the three and
nine month periods ended September 30, 2007 were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
(Dollars in thousands)
|
|
|
Net revenues
|
|
$
|
197,502
|
|
|
$
|
720,285
|
|
Costs and other expenses, net
|
|
|
189,788
|
|
|
|
677,091
|
|
Loss (gain) on dispositions
|
|
|
275
|
|
|
|
(75,215
|
)
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations before income taxes
|
|
|
7,439
|
|
|
|
118,409
|
|
Provision for income taxes
|
|
|
1,251
|
|
|
|
41,163
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
$
|
6,188
|
|
|
$
|
77,246
|
|
|
|
|
|
|
|
|
|
|
22
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
Forward-Looking
Statements
All statements made in this Quarterly Report on
Form 10-Q,
other than statements of historical fact, are forward-looking
statements. The words anticipate,
believe, estimate, expect,
intend, may, plan,
will, would, should,
guidance, potential,
continue, project, forecast,
confident, prospects, and similar
expressions typically are used to identify forward-looking
statements. Forward-looking statements are based on the
then-current expectations, beliefs, assumptions, estimates and
forecasts about our business and the industry and markets in
which we operate. These statements are not guarantees of future
performance and are subject to risks, uncertainties and
assumptions which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is
expressed or implied by these forward-looking statements due to
a number of factors, including changes in business relationships
with and purchases by or from major customers or suppliers,
including delays or cancellations in shipments; demand for and
market acceptance of new and existing products; our ability to
integrate acquired businesses into our operations, particularly
Arrow International Inc., realize planned synergies and operate
such businesses profitably in accordance with expectations; our
ability to effectively execute our restructuring programs;
competitive market conditions and resulting effects on revenues
and pricing; increases in raw material costs that cannot be
recovered in product pricing; and global economic factors,
including currency exchange rates and interest rates;
difficulties entering new markets; and general economic
conditions. For a further discussion of the risks relating to
our business, see Item 1A of our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007. We expressly
disclaim any obligation to update these forward-looking
statements, except as otherwise specifically stated by us or as
required by law or regulation.
Overview
Teleflex strives to maintain a portfolio of businesses that
provide consistency of performance, improved profitability and
sustainable growth. To this end, in 2007 we significantly
changed the composition of our portfolio through acquisitions
and divestitures to improve margins, reduce cyclicality and
focus our resources on the development of our core businesses.
We continually evaluate the composition of the portfolio of our
businesses to ensure alignment with our overall objectives.
On October 1, 2007, we acquired all of the outstanding
capital stock of Arrow International, Inc. (Arrow)
for approximately $2.1 billion including fees and expenses.
Arrow is a leading global provider of catheter-based access and
therapeutic products for critical and cardiac care. In November
2007, we acquired Nordisk Aviation Products a.s. (Nordisk), a
world leader in developing, supplying and servicing containers
and pallets for air cargo, for approximately $27.8 million,
net of cash acquired. The results of Arrow and Nordisk have been
included in our Medical and Aerospace segments, respectively,
since their respective acquisition dates.
On June 29, 2007, we completed the sale of Teleflex
Aerospace Manufacturing Group (TAMG), a
precision-machined components business in our Aerospace Segment,
for $133.9 million in cash. On December 27, 2007, we
completed the sale of our business units that design and
manufacture automotive and industrial driver controls, motion
systems and fluid handling systems (the GMS
businesses) for $560 million in cash. The sale price
is subject to possible adjustment based on the working capital
of the business, measured at the closing date of the sale. In
the second quarter of 2008, we refined our estimates of the
post-closing adjustment based on the working capital of the
business. In addition, we also recorded a charge for the
settlement of a contingency related to the GMS businesses. These
activities resulted in a reduction to the gain on sale of the
GMS businesses of approximately $2.8 million, net of taxes
of $2.0 million for the nine months ending
September 28, 2008 which is reported as a loss from
discontinued operations. For the three and nine month periods
ending September 30, 2007 the TAMG and GMS businesses have
been presented in our condensed consolidated financial
statements as discontinued operations.
The Medical, Aerospace and Commercial segments comprised 62%,
21% and 17% of our revenues, respectively, for the nine months
ended September 28, 2008 and comprised 50%, 25% and 25% of
our revenues, respectively, for the same period in 2007.
23
Critical
Accounting Estimates
Preparation of our financial statements requires management to
make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. We believe the
most complex and sensitive judgments, because of their
significance to the Consolidated Financial Statements, result
primarily from the need to make estimates about the effects of
those matters that are inherently uncertain and may have a
material impact on our financial condition and results of
operations. Managements Discussion and Analysis and
Note 1 to the Consolidated Financial Statements in our 2007
Form 10-K,
describe the critical accounting estimates used in preparation
of the Consolidated Financial Statements. Actual results in
these areas could differ from managements estimates. As
discussed below and in Note 11 to the Condensed
Consolidated Financial Statements included in this report, we
have adopted Statement of Financial Accounting Standards
(SFAS) No. 157 as of January 1, 2008, with
the exception of the application of the statement to
nonrecurring nonfinancial assets and nonfinancial liabilities,
the deferral of which was permitted under FASB Staff Position
No. 157-2.
In addition,
FSP 157-3
was issued and effective in October 2008. Other than this
change, there have been no significant changes in our critical
accounting estimates during the first nine months of 2008.
In measuring fair value including the key considerations
clarified in
FSP 157-3,
we have reconfirmed our initial determination that financial
assets are comprised of both Level 1 and Level 2
inputs in active markets and that our financial liabilities are
comprised of Level 2 inputs, as defined under SFAS 157
and as described in Note 11 to the Condensed Consolidated
Financial Statements included in this report. Although the
potential risk to us is the replacement cost of the then
estimated fair value of these instruments, management believes
that the risk of losses is remote and that the losses, if any,
would be immaterial.
Results
of Operations
We are focused on achieving consistent and sustainable growth
through the development of new products, expansion of market
share, moving existing products into new geographies, and
through selected acquisitions which enhance or expedite our
development initiatives and our ability to increase market
share. The discussion of growth from acquisitions included below
reflects the impact of a purchased company up to twelve months
from the date of acquisition. Activity after the initial twelve
months is considered core growth. Core growth excludes the
impact of translating the results of international subsidiaries
at different currency exchange rates from year to year and the
comparable activity of divested companies within the most recent
twelve-month period.
Comparison
of the three and nine month periods ended September 28,
2008 and September 30, 2007
Revenues increased approximately 30% in the third quarter of
2008 to $595.9 million from $458.6 million in the same
period of a year ago. Businesses acquired in 2007 were
responsible for the entire increase. Revenue from core
businesses declined 4% during the quarter which was largely
offset by a 3% favorable impact on revenues from foreign
currency translation. For the first nine months of 2008,
revenues increased approximately 35% to $1.8 billion from
$1.4 billion in the first nine months of 2007. Businesses
acquired in the past twelve months contributed 34% to this
increase in revenues and foreign currency translation
contributed 4% to revenue growth, while revenues from core
business declined 2% and divestitures reduced revenues by
another 1%. Core revenue decline in the third quarter and first
nine months of 2008 was primarily due to a significant decrease
in sales volume for auxiliary power units sold into the North
American truck market and sales of recreational marine products,
and to a lesser extent, weaker sales of surgical and critical
care products in North America.
Gross profit as a percentage of revenues increased to 40.1% in
the third quarter of 2008 from 33.6% in the third quarter of
2007. For the first nine months of 2008, gross profit as a
percentage of revenues increased to 40.0% compared to 35.4% for
the nine months of 2007. For both the three month and nine month
periods, the increases were largely due to the addition of
higher margin Arrow critical care product lines and improved
margins in the Aerospace Segments engine repairs business.
Selling, engineering and administrative expenses (operating
expenses) as a percentage of revenues were 24.2% for the three
months ended September 28, 2008 compared to 20.9% for the
three months ended September 30, 2007 and 25.2% for the
first nine months of 2008 compared to 22.0% for the first nine
months of 2007, principally due to the acquisition of Arrow.
24
Interest expense increased significantly in the third quarter
and first nine months of 2008 compared to the same periods in
2007 principally as a result of the debt incurred in connection
with the Arrow acquisition. Interest income decreased in the
third quarter and first nine months of 2008 compared to the same
periods in 2007 primarily due to lower amounts of invested funds
combined with lower average interest rates. The effective tax
rate for the three months ending September 28, 2008 was
20.9% compared to 215.9% for the corresponding prior year
period. For the nine months ending September 28, 2008 the
effective tax rate was 24.2% compared to 83.8% for the
corresponding prior year period. The rate decrease in both
periods reflects the discrete income tax charge in the third
quarter of 2007 of approximately $90.2 million in
anticipation of the Arrow acquisition. Specifically, in
connection with funding the acquisition of Arrow, the Company
(i) repatriated approximately $197.0 million of cash
from foreign subsidiaries which had previously been deemed to be
permanently reinvested in the respective foreign jurisdictions;
and (ii) changed its position with respect to certain
additional previously untaxed foreign earnings to treat these
earnings as no longer permanently reinvested. Minority interest
in consolidated subsidiaries increased $2.4 million and
$4.8 million in the third quarter and first nine months of
2008, respectively compared to the same periods in 2007 due to
increased profits during the third quarter of 2008 from
consolidated entities that are not wholly-owned.
In connection with the acquisition of Arrow, we have formulated
a plan related to the future integration of Arrow and our
Medical businesses. The integration plan focuses on the closure
of Arrow corporate functions and the consolidation of
manufacturing, sales, marketing and distribution functions in
North America, Europe and Asia. Costs related to actions that
affect employees and facilities of Arrow have been included in
the allocation of the purchase price of Arrow. Costs related to
actions that affect employees and facilities of Teleflex are
charged to earnings and included in restructuring and impairment
charges within the condensed consolidated statement of
operations. These costs amounted to approximately
$0.4 million and $11.2 million during the three and
nine months ended September 28, 2008, respectively. As of
September 28, 2008, we estimate that the aggregate of
future restructuring and impairment charges that we will incur
are approximately $22.0 $25.0 million in 2008
and 2009 in connection with the Arrow integration plan. Of this
amount, $10.3 $11.3 million relates to employee
termination costs, $10.5 $11.5 million relates
to costs associated with the termination of leases and certain
distribution agreements and $1.2 $2.2 million
relates to other restructuring costs. The Company has also
incurred restructuring related costs in the Medical Segment
which do not qualify for classification as restructuring costs.
For the three and nine months ended September 28, 2008,
these costs amounted to $2.1 million and $5.9 million,
respectively and are reported in the results of the Medical
Segments operating profit in selling, engineering and
administrative expenses.
In June 2006, we began certain restructuring initiatives that
affect all three of our operating segments. These initiatives
involved the consolidation of operations and a related reduction
in workforce at several of our facilities in Europe and North
America. We determined to undertake these initiatives to improve
operating performance and to better leverage our existing
resources. The charges, including changes in estimates,
associated with the 2006 restructuring program that are included
in restructuring and impairment charges within the condensed
consolidated statement of operations amounted to approximately
$38 thousand and $1.1 million for the three month periods
ended September 28, 2008 and September 30, 2007,
respectively and $705 thousand and $2.0 million for the
nine month periods ended September 28, 2008 and
September 30, 2007, respectively. As of September 28,
2008, we expect to incur approximately $228 thousand in contract
termination costs under our 2006 restructuring program.
For additional information regarding our restructuring programs,
see Note 4 to our Condensed Consolidated Financial
Statements included in this report.
25
Segment
Review
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
% Increase/
|
|
|
September 28,
|
|
|
September 30,
|
|
|
% Increase/
|
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
|
(Dollars in thousands)
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
367,327
|
|
|
$
|
227,825
|
|
|
|
61
|
|
|
$
|
1,125,719
|
|
|
$
|
681,142
|
|
|
|
65
|
|
Aerospace
|
|
|
126,927
|
|
|
|
113,747
|
|
|
|
12
|
|
|
|
385,765
|
|
|
|
331,351
|
|
|
|
16
|
|
Commercial
|
|
|
101,628
|
|
|
|
116,990
|
|
|
|
(13
|
)
|
|
|
313,003
|
|
|
|
338,726
|
|
|
|
(8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment net revenues
|
|
|
595,882
|
|
|
|
458,562
|
|
|
|
30
|
|
|
|
1,824,487
|
|
|
|
1,351,219
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
71,388
|
|
|
|
50,448
|
|
|
|
42
|
|
|
|
212,952
|
|
|
|
142,275
|
|
|
|
50
|
|
Aerospace
|
|
|
16,786
|
|
|
|
7,544
|
|
|
|
123
|
|
|
|
45,912
|
|
|
|
32,174
|
|
|
|
43
|
|
Commercial
|
|
|
7,067
|
|
|
|
2,304
|
|
|
|
207
|
|
|
|
19,374
|
|
|
|
18,010
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating profit
|
|
$
|
95,241
|
|
|
$
|
60,296
|
|
|
|
58
|
|
|
$
|
278,238
|
|
|
$
|
192,459
|
|
|
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The percentage increases or (decreases) in net revenues during
the three and nine month periods ended September 28, 2008
compared to the same period in 2007 are due to the following
factors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Increase/(Decrease)
|
|
|
|
2008 vs. 2007
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Commercial
|
|
|
Total
|
|
|
|
Three
|
|
|
Nine
|
|
|
Three
|
|
|
Nine
|
|
|
Three
|
|
|
Nine
|
|
|
Three
|
|
|
Nine
|
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Acquisitions
|
|
|
57
|
|
|
|
60
|
|
|
|
12
|
|
|
|
12
|
|
|
|
|
|
|
|
3
|
|
|
|
31
|
|
|
|
34
|
|
Core growth
|
|
|
1
|
|
|
|
1
|
|
|
|
(2
|
)
|
|
|
1
|
|
|
|
(13
|
)
|
|
|
(12
|
)
|
|
|
(4
|
)
|
|
|
(2
|
)
|
Currency translation
|
|
|
3
|
|
|
|
5
|
|
|
|
2
|
|
|
|
3
|
|
|
|
1
|
|
|
|
2
|
|
|
|
3
|
|
|
|
4
|
|
Dispositions
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Change
|
|
|
61
|
|
|
|
65
|
|
|
|
12
|
|
|
|
16
|
|
|
|
(13
|
)
|
|
|
(8
|
)
|
|
|
30
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a discussion of our segment operating results.
Comparison
of the three and nine month periods ended September 28,
2008 and September 30, 2007
Medical
Medical Segment net revenues grew 61% in the third quarter of
2008 to $367.3 million, from $227.8 million in the
same period last year. The acquisition of Arrow accounted for
$129.6 million, or 57%, of this increase in revenues. Of
the remaining 4% increase in net revenues, 3% was due to foreign
currency fluctuations and 1% was due to core revenue growth.
Medical Segment core revenue growth in the third quarter
compared to the same period in 2007 reflects higher sales volume
for critical care and surgical products in Europe and Asia/Latin
America, offsetting lower sales volumes for critical care and
surgical products in North America and an increase in sales of
specialty medical devices to original equipment manufacturers
(OEM).
26
Medical Segment net revenues include sales of critical care,
surgical and cardiac care products as well as sales of medical
devices to original equipment manufacturers. Net sales by
product group are comprised of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
% Increase/
|
|
|
September 28,
|
|
|
September 30,
|
|
|
% Increase/
|
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
|
(Dollars in millions)
|
|
|
Critical Care
|
|
$
|
228.8
|
|
|
$
|
113.7
|
|
|
|
101
|
|
|
$
|
709.4
|
|
|
$
|
345.1
|
|
|
|
106
|
|
Surgical
|
|
|
76.6
|
|
|
|
73.3
|
|
|
|
5
|
|
|
|
224.9
|
|
|
|
215.1
|
|
|
|
5
|
|
Cardiac Care
|
|
|
16.0
|
|
|
|
|
|
|
|
100
|
|
|
|
56.7
|
|
|
|
|
|
|
|
100
|
|
OEM
|
|
|
39.4
|
|
|
|
38.1
|
|
|
|
3
|
|
|
|
118.2
|
|
|
|
108.4
|
|
|
|
9
|
|
Other
|
|
|
6.5
|
|
|
|
2.7
|
|
|
|
141
|
|
|
|
16.5
|
|
|
|
12.5
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenues
|
|
$
|
367.3
|
|
|
$
|
227.8
|
|
|
|
61
|
|
|
$
|
1,125.7
|
|
|
$
|
681.1
|
|
|
|
65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Arrow acquisition contributed a total of $129.6 million
and $403.1 million to Medical Segment revenues for the
three and nine month periods ended September 28, 2008,
respectively, of which $113.6 million and
$346.4 million are included in the critical care product
group and $16.0 million and $56.7 million are included
in the cardiac care product category for the three and nine
month periods ended September 28, 2008, respectively.
Medical Segment net revenues include sales of critical care,
surgical and cardiac care products to hospitals and healthcare
providers, which represents 89% of the Medical Segments
net revenues for the first nine months of 2008 and are
geographically comprised of the following:
|
|
|
|
|
North America
|
|
|
43
|
%
|
Europe, Middle East and Africa
|
|
|
36
|
%
|
Asia and Latin America
|
|
|
10
|
%
|
|
|
|
|
|
|
|
|
89
|
%
|
|
|
|
|
|
The remaining 11% of the Medical Segments net revenues are
derived from sales of medical devices to original equipment
manufacturers.
Critical care product sales increased during the third quarter
of 2008 as compared to the corresponding prior year period. This
increase was almost entirely due to the acquisition of Arrow in
the fourth quarter of 2007, which expanded our vascular access
and regional anesthesia product lines and contributed
$113.6 million to the critical care category during the
quarter. Sales of respiratory care products decreased overall as
lower sales in North America offset the impact of favorable
foreign currency translation and stronger sales volume in Europe
and Asia/Latin America. Anesthesia sales increased overall due
to favorable foreign currency translation and higher volume in
Europe and Asia/Latin America. Urology product sales increased
mainly due to favorable exchange rates in Europe and slightly
higher volume in Asia/Latin America, which was partially offset
by a slight volume decline in North America. For the first nine
months of 2008, critical care product sales increased compared
to the same period of a year ago primarily due to the addition
of the Arrow products ($346.4 million). Other factors that
account for the remaining $17.9 million of sales growth
during the nine months ended September 28, 2008 include
favorable foreign currency translation and increased volume for
respiratory and anesthesia products in Europe and Asia/Latin
America.
Surgical product sales increased approximately 5% during the
third quarter of 2008 compared to the same period of a year ago
benefiting from favorable foreign currency translation and
higher volumes for certain product lines. Increased sales of
surgical products in European and Asia/Latin American markets
were partially offset by declines in surgical device sales in
North America compared to the corresponding prior year quarter.
This decline was primarily in the chest drainage and
instrumentation product lines. For the first nine months of
2008, surgical product sales increased 5%, largely as a result
of favorable foreign currency translation and higher volume for
surgical products in European markets.
Cardiac care product sales increased as a result of the Arrow
acquisition in the fourth quarter of 2007, which added
$16.0 million and $56.7 million in revenues for this
product category in the three and nine month periods ended
September 28, 2008, respectively.
27
Sales to original equipment manufacturers increased during the
third quarter of 2008 as compared to the comparable prior year
period primarily as a result of higher volumes for specialty
suture products and other specialty devices. For the first nine
months of 2008, sales to original equipment manufacturers
increased primarily as a result of an acquisition in the
orthopedic product line in early 2007, increased sales of
orthopedic instrumentation and higher volumes for specialty
sutures and other devices.
Operating profit in the Medical Segment increased 42% during the
third quarter of 2008 to $71.4 million, from
$50.4 million in the corresponding prior year period. For
the first nine months of 2008, segment operating profit
increased 50% to $213.0 million, from $142.3 million
in the corresponding prior year period. For both periods, the
addition of higher margin Arrow critical care product lines was
the principal factor that caused the higher segment operating
profit. Other factors that contributed to the higher operating
profit were improved cost and operational efficiencies, higher
volumes in Europe and Asia/Latin America and the favorable
impact from the stronger Euro.
Aerospace
Aerospace Segment revenues grew 12% in the third quarter of 2008
to $126.9 million, from $113.7 million in the
corresponding prior year period. The expansion of the cargo
containers product line with the acquisition of Nordisk Aviation
Products accounted for all of this growth during the quarter.
Foreign currency fluctuations of 2% offset a 2% decline in core
growth. The decrease in core revenues reflects lower unit
volumes for wide body cargo-handling systems during the quarter
which more than offset higher volumes for narrow body
cargo-handling systems and higher cargo aftermarket replacement
parts sales and repairs. Core revenues from engine repair
products and services also decreased compared to the
corresponding prior year quarter reflecting the shift towards
higher margin engine repair services contrasted with higher
priced, lower margin replacement parts sales. For the first nine
months of 2008 Aerospace revenues grew 16% to
$385.8 million, from $331.4 million in the
corresponding prior year period. This growth was principally due
to the impact of the Nordisk acquisition and increased sales of
wide body cargo handling systems, narrow body cargo loading
systems and cargo spare components and repairs.
Segment operating profit increased 123% in the third quarter of
2008 to $16.8 million, from $7.5 million in the
corresponding prior year period. For the first nine months of
2008, segment operating profit increased 43% to
$45.9 million compared to $32.2 million in the
corresponding prior year period. For both periods, the increase
was principally due to the impact of the Nordisk acquisition,
favorable product mix in the engine repair services business
resulting from higher volume for engine repair and lower demand
for replacement parts compared to the corresponding prior year
period and from consolidation of operations and phasing out of
lower margin product lines in the engine repair services
business during 2007.
Commercial
Commercial Segment revenues declined approximately 13% in the
third quarter of 2008 to $101.6 million, from
$117.0 million in the same period last year. Core growth of
9% in sales of rigging services products was more than offset by
lower sales of auxiliary power units for the North American
truck market and sharply lower sales of marine products
resulting in an overall decline in core revenue of 13% in the
Commercial Segment. Foreign currency contributed 1%, offset by
dispositions of 1%. For the first nine months of 2008 Commercial
revenues declined 8% to $313.0 million, from
$338.7 million during the corresponding prior year period
as a result of a decline in sales of auxiliary power units for
the North American truck market and to a decline in sales of
marine products for the recreational boat market, offset by
benefits of 3% from the Southern Wire acquisition.
During the third quarter of 2008, operating profit in the
Commercial Segment increased 207% to $7.1 million, from
$2.3 million in the corresponding prior year period. This
increase was due principally to favorable product mix in the
rigging services business and the favorable comparison to the
same period of a year ago from approximately $4 million of
provisions in the third quarter of 2007 for warranty and other
costs related to prior generation auxiliary power units which
did not recur during the current quarter, which offset the
impact from lower sales volumes in the power systems and marine
businesses. For the first nine months of 2008, segment operating
profit increased 8% to $19.4 million compared to
$18.0 million in the corresponding prior year period. The
increase in operating profit for both periods was principally
due to the non-recurrence of warranty costs related to prior
generation auxiliary power units and favorable product mix in
the rigging services business which offset unfavorable foreign
currency fluctuation and lower volumes in the power systems and
marine businesses.
28
Liquidity
and Capital Resources
Operating activities from continuing operations provided net
cash of approximately $98.1 million during the first nine
months of 2008. The change in operating assets and liabilities
resulted in a decrease in cash from operations of approximately
$140.6 million during the first nine months of 2008
primarily due to approximately $90.2 million of estimated
tax payments made in connection with businesses divested during
the fourth quarter of 2007. Our financing activities from
continuing operations during the first nine months of 2008
consisted primarily of proceeds from long-term debt of
$77.0 million, repayment of long-term debt of approximately
$185.3 million, payment of dividends of $39.6 million
and payments to minority interest shareholders of
$33.1 million. Our investing activities from continuing
operations during the first nine months of 2008 consisted
primarily of capital expenditures of $28.3 million and
$5.7 million of additional payments for businesses acquired
primarily Nordisk. Cash flows used in discontinued operations of
$5.6 million reflects the settlement of a contingency
related to the sale of the GMS businesses.
We use an accounts receivable securitization program to gain
access to enhanced credit markets and reduce financing costs. As
currently structured, we sell certain trade receivables on a
non-recourse basis to a consolidated special purpose entity
which in turn sells interests in those receivables to a
commercial paper conduit. The conduit issues notes secured by
those interests to third party investors. The assets of the
special purpose entity are not available to satisfy our
obligations. The total amount of accounts receivable held by the
special purpose entity at September 28, 2008 and
December 31, 2007 were $147.6 million and
$124.3 million, respectively. The special purpose entity
has received cash consideration of $39.7 million for the
interests in the accounts receivable it has sold to the
commercial paper conduit at each of September 28, 2008 and
December 31, 2007 which amounts were removed from the
consolidated balance sheet at such dates in accordance with
SFAS 140, Accounting for Transfers and Servicing of
Financial Assets and Extinguishments of Liabilities.
On June 14, 2007, our Board of Directors authorized the
repurchase of up to $300 million of our outstanding common
stock. Repurchases of our stock under the Board authorization
may be made from time to time in the open market and may include
privately-negotiated transactions as market conditions warrant
and subject to regulatory considerations. The stock repurchase
program has no expiration date and our ability to execute on the
program will depend on, among other factors, cash requirements
for acquisitions, cash generation from operations, debt
repayment obligations, market conditions and regulatory
requirements. In addition, under the senior loan agreements
entered into October 1, 2007, we are subject to certain
restrictions relating to our ability to repurchase shares in the
event our consolidated leverage ratio exceeds certain levels,
which may further limit our ability to repurchase shares under
this Board authorization. Through September 28, 2008, no
shares have been purchased under this Board authorization.
The following table provides our net debt to total capital ratio:
|
|
|
|
|
|
|
|
|
|
|
September 28,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Net debt includes:
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
89,915
|
|
|
$
|
143,357
|
|
Long-term borrowings
|
|
|
1,488,396
|
|
|
|
1,540,902
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
1,578,311
|
|
|
|
1,684,259
|
|
Less: Cash and cash equivalents
|
|
|
91,397
|
|
|
|
201,342
|
|
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
1,486,914
|
|
|
$
|
1,482,917
|
|
|
|
|
|
|
|
|
|
|
Total capital includes:
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
1,486,914
|
|
|
$
|
1,482,917
|
|
Shareholders equity
|
|
|
1,386,619
|
|
|
|
1,328,843
|
|
|
|
|
|
|
|
|
|
|
Total capital
|
|
$
|
2,873,533
|
|
|
$
|
2,811,760
|
|
|
|
|
|
|
|
|
|
|
Percent of net debt to total capital
|
|
|
52
|
%
|
|
|
53
|
%
|
29
As of September 28, 2008, the aggregate amount of debt
maturing for each year is as follows (dollars in millions):
|
|
|
|
|
Remaining 2008
|
|
$
|
38.8
|
|
2009
|
|
|
103.5
|
|
2010
|
|
|
102.2
|
|
2011
|
|
|
247.2
|
|
2012
|
|
|
860.1
|
|
2013 and thereafter
|
|
|
226.5
|
|
We believe that our cash flow from operations and our ability to
access additional funds through our existing credit facilities
will enable us to fund our operating requirements and capital
expenditures and meet debt obligations. As of September 28,
2008, there was $355.2 million available under our
revolving credit facility.
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
There have been no significant changes in market risk for the
quarter ended September 28, 2008 from those addressed in
the Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007. See the
information set forth in Part II, Item 7A of the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007.
|
|
Item 4.
|
Controls
and Procedures
|
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of the end of the
period covered by this report. Based on that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures as of the end of the
period covered by this report are functioning effectively to
provide reasonable assurance that the information required to be
disclosed by us in reports filed under the Securities Exchange
Act of 1934 is (i) recorded, processed, summarized and
reported within the time periods specified in the SECs
rules and forms and (ii) accumulated and communicated to
our management, including the Chief Executive Officer and Chief
Financial Officer, as appropriate to allow timely decisions
regarding disclosure. A controls system cannot provide absolute
assurance that the objectives of the controls system are met,
and no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within a
company have been detected.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting
occurred during our most recent fiscal quarter that has
materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
30
PART II
OTHER INFORMATION
|
|
Item 1.
|
Legal
Proceedings
|
On October 11, 2007, the Companys subsidiary, Arrow
International, Inc. (Arrow), received a corporate
warning letter from the U.S. Food and Drug Administration
(FDA). The letter cites three site-specific warning letters
issued by the FDA in 2005 and subsequent inspections performed
from June 2005 to February 2007 at Arrows facilities in
the United States. The letter expresses concerns with
Arrows quality systems, including complaint handling,
corrective and preventive action, process and design validation,
inspection and training procedures. It also advises that
Arrows corporate-wide program to evaluate, correct and
prevent quality system issues has been deficient. Limitations on
pre-market approvals and certificates of foreign goods had
previously been imposed on Arrow based on prior inspections and
the corporate warning letter does not impose additional
sanctions that are expected to have a material financial impact
on the Company.
In connection with its acquisition of Arrow, completed on
October 1, 2007, the Company has developed an integration
plan that includes the commitment of significant resources to
correct these previously-identified regulatory issues and
further improve overall quality systems. Senior management
officials from the Company have met with FDA representatives,
and a comprehensive written corrective action plan was presented
to FDA in late 2007. The Company has begun implementing its
corrective action plan, which it expects to complete, for most
facilities and procedures, by the end of 2008.
While the Company believes it can remediate these issues, there
can be no assurances regarding the length of time or cost it
will take the Company to resolve these issues to the
satisfaction of the FDA. If the Companys remedial actions
are not satisfactory to the FDA, it may have to devote
additional financial and human resources to its efforts, and the
FDA may take further regulatory actions against the Company,
including, but not limited to, seizing its product inventory,
obtaining a court injunction against further marketing of the
Companys products or assessing civil monetary penalties.
In June 2008, HM Revenue and Customs (HMRC) assessed
Airfoil Technologies International UK Limited
(ATI-UK), a consolidated United Kingdom venture in
which the Company has a 60% economic interest, approximately
$13 million for customs duty for the period from
July 1, 2005 through March 31, 2008. HMRC had
previously assessed ATI-UK approximately $1 million for
customs duty for the first and second quarters of 2004.
Additionally, for the above periods, ATI-UK was assessed a value
added tax (VAT) of approximately $93 million,
for which HMRC has advised ATI-UK that, to the extent it is due
and payable, it has until March 2010 to fully recover such VAT.
The assessments were imposed because HMRC concluded that ATI-UK
did not provide the necessary documentation for which reliance
on Inland Processing Relief status (duty and VAT) was claimed by
ATI-UK.
ATI-UK has filed appeals and been granted hardship applications
(to avoid payment of the assessment while the appeal is pending)
regarding each of the assessments. ATI-UK has provided certain
documentation to HMRC and is continuing to assemble
documentation for submission to HMRC and intends to vigorously
contest these assessments. In the event ATI-UK is not successful
in a favorable resolution of the assessments, such outcome would
have a material adverse effect on the business of ATI-UK. The
Company has a net investment in ATI-UK of approximately
$12 million.
In addition, the Company is a party to various lawsuits and
claims arising in the normal course of business. These lawsuits
and claims include actions involving product liability,
intellectual property, employment and environmental matters.
Based on information currently available, advice of counsel,
established reserves and other resources, the Company does not
believe that any such actions are likely to be, individually or
in the aggregate, material to its business, financial condition,
results of operations or liquidity. However, in the event of
unexpected further developments, it is possible that the
ultimate resolution of these matters, or other similar matters,
if unfavorable, may be materially adverse to the Companys
business, financial condition, results of operations or
liquidity.
31
There have been no significant changes in risk factors for the
quarter ended September 28, 2008 from those addressed in
the Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007. See the
information set forth in Part I, Item 1A of the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007.
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
Not applicable.
|
|
Item 3.
|
Defaults
Upon Senior Securities
|
Not applicable.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
Not applicable.
|
|
Item 5.
|
Other
Information
|
Not applicable.
32
The following exhibits are filed as part of this report:
|
|
|
|
|
|
|
Exhibit No.
|
|
|
|
Description
|
|
|
31
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
31
|
.2
|
|
|
|
Certification of Chief Financial Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
32
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
|
32
|
.2
|
|
|
|
Certification of Chief Financial Officer, Pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
33
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
TELEFLEX INCORPORATED
Jeffrey P. Black
Chairman and
Chief Executive Officer
(Principal Executive Officer)
Kevin K. Gordon
Executive Vice President and
Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
By:
|
/s/ Charles
E. Williams
|
Charles E. Williams
Corporate Controller and
Chief Accounting Officer
(Principal Accounting Officer)
Dated: October 28, 2008
34